CBD for Anxiety

Verdict: Disputed and weak: best trials show no benefit

The evidence that CBD relieves anxiety is genuinely split and rated weak: the largest, highest-quality meta-analysis found no benefit, and the strongest positive signals come only from single-dose, public-speaking experiments rather than from treating a diagnosed anxiety disorder. CBD also is not a legal supplement ingredient in many places and carries real drug-interaction and liver-safety concerns.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The research directly contradicts itself, which is why this lands at a weak, disputed grade rather than a clear yes or no. The largest and best-conducted synthesis to date, a 2026 meta-analysis of 54 randomized trials in 2,477 people (PMID 41856154), found no significant effect of cannabinoids on anxiety. A smaller 2024 meta-analysis (PMID 38924898) did report a large benefit, but it pooled just 316 participants with a confidence interval that barely cleared zero (Hedges g -0.92, 95% CI -1.80 to -0.04), making the estimate fragile.

The positive signals are also narrow in scope. The most consistent effects appear in acute, single-dose experiments — such as a 600 mg dose easing nerves before a simulated public-speaking task (PMID 21307846) and reviews of social-anxiety challenge studies (PMID 36875967). A narrative review of 11 trials (PMID 39598172) called the results across studies contradictory. Well-powered, longer-term trials in people with a diagnosed anxiety disorder are essentially missing, and dosing varies enormously.

Regulators and major clinics reinforce the caution. The US FDA states CBD is not an appropriate dietary-supplement or food ingredient; the UK's food regulator advises healthy adults cap intake at about 10 mg per day and that vulnerable groups avoid it entirely; and Mayo Clinic calls human evidence too limited to be definitive, while flagging drug interactions, possible liver effects, and unreliable product labeling. WHO notes a generally good safety profile but does not endorse CBD for anxiety.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
74%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.25
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L11 AI re-checkIndependent read
0.50
L1 ExamineGlobal benchmark
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.446
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 2 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis
PMID: 41856154 2026 統合分析 n = 2,477
Finding: Largest meta-analysis to date (54 RCTs, 2477 participants, 1980 to May 2025). Found no significant effect of cannabinoids on anxiety outcomes, nor on PTSD, psychotic disorders, anorexia nervosa or opioid use disorder. No RCTs existed for depression. Concluded the evidence does not support cannabinoids as a treatment for anxiety.
🟢 High quality Mixed funding Effect size: No significant effect for anxiety (NS)
View on PubMed
Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
PMID: 38924898 2024 統合分析 n = 316
Finding: Pooled 8 trials (316 participants) and found a substantial significant anxiolytic effect of CBD with a large effect size (Hedges g -0.92, 95% CI -1.80 to -0.04). Authors explicitly cautioned that the very small clinical sample and wide confidence interval limit interpretation.
🟠 Limited quality Effect size: Hedges g -0.92 (95% CI -1.80 to -0.04)
View on PubMed
The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
PMID: 39598172 2024 系統性回顧
Finding: Identified 11 RCTs (from 284 articles, 2013 to 2023). CBD may reduce anxiety with minimal adverse effects compared with placebo, but results across studies were often contradictory; authors call for further RCTs with improved methodology, a broad dose range and continuous administration.
Effect size: not pooled (narrative synthesis)
View on PubMed
Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety
PMID: 36875967 2022 Other
Finding: Acute CBD administration significantly decreased anxiety without sedation in both healthy volunteers and SAD patients; a single chronic study showed reduced SAD symptoms. Authors conclude CBD may be a promising treatment for SAD but flag unresolved gaps in optimal dose, timecourse, long-term effects and sex differences.
Government Effect size: not pooled (narrative synthesis)
View on PubMed
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients
PMID: 21307846 2011 RCT (double-blind) n = 36
Finding: In 24 treatment-naive social anxiety disorder patients (plus 12 healthy controls), a single 600 mg CBD dose significantly reduced anxiety, cognitive impairment and discomfort during the public speaking test, bringing SAD patients close to the healthy-control response. Demonstrates an acute experimental-anxiety effect, not a chronic clinical-disorder outcome.
Effect size: significant reduction vs placebo (effect size not reported)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
Today, the U.S. Food and Drug Administration announced that the agency has concluded that a new regulatory pathway for CBD is needed... the agency has concluded that existing regulatory frameworks for foods and supplements are not appropriate for CBD. source↗
L4b EU EFSA
Against
L4c UK NHS
Cautious
Healthy adults should think carefully before taking CBD, and should consider limiting their consumption of CBD from food to no more than 10mg per day, which is about 4-5 drops of 5% CBD oil. The FSA continues to advise that CBD is not taken by people in vulnerable groups, including children, people taking medication and those who are pregnant or breastfeeding and those trying to conceive. source↗
L4d TW TFDA / 衛福部
Against
大麻二酚(CBD)不屬於毒品及管制藥品,考量其具有非常多藥理活性及可能的醫療用途,我國以一般藥品列管。 source↗
L4e WHO
Not addressed
In general, CBD is well tolerated with a good safety profile... To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD. [WHO ECDD Cannabidiol (CBD) Critical Review Report, June 2018] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Against
There are many intriguing findings in pre-clinical studies that suggest CBD and hemp oil have anti-inflammatory effects and may be helpful with improving sleep and anxiety. But trials in humans are still limited, so it is too early to be definitive about efficacy and safety. source↗
L5c Cleveland Clinic
Against
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-cannabidiol-001 繁體中文版 →